271 results on '"Krämer, Alwin"'
Search Results
2. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
3. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
4. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
5. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
6. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
7. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
8. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
9. Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability
10. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
11. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
12. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
13. A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma
14. Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
15. Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution
16. Centrosome amplification in tumorigenesis
17. Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum
18. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
19. Protocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells
20. Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
21. Aneuploidy Precedes and Segregates with Chemical Carcinogenesis
22. Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial
23. Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial
24. A Semi-Automated Knime-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations
25. High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia
26. Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
27. Cohesin Subunit SMC3 Levels Impact on Karyotype and Outcome in Acute Myeloid Leukemia
28. Validation of the ELN 2017 Classification for AML with Intermediate Risk Cytogenetics with or without NPM1 -Mutations and High or Low Ratio FLT3-ITD s
29. The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial
30. Minimal-Residual Disease Guided Treatment with Azacitidine in MDS/AML Patients at Imminent Risk of Relapse: Results of the Prospective RELAZA2 Trial
31. Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC) in Elderly Patients: Results of a Treatment Algorithm Employing Allogeneic Stem Cell Transplantation with Moderately Reduced Conditioning Intensity
32. Allogeneic Stem Cell Transplantation Improves Survival in Patients with FLT3-ITD-Negative and NPM1-Wild Type Intermediate Risk (ELN) Acute Myeloid Leukemia
33. Marker Chromosomes Can Arise from Chromothripsis and Predict Adverse Prognosis in Acute Myeloid Leukemia
34. Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies
35. Pretransplant NPM1 -MRD Levels Predict Outcome after Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia
36. Adverse Prognosis in Acute Myeloid Leukemia with Abnormality Abn(3q): Does EVI1 Matter?
37. Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial
38. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia
39. Efficacy Of Azacitidine Versus Low-Dose Cytarabine In Patients With Acute Myeloid Leukemia - A Retrospective Single Center Experience
40. Pre-Transplant Weight Loss and Total Serum Protein Predict Relapse Of Acute Myeloid Leukaemia After Allogeneic Stem Cell Transplantation
41. Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment
42. Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial
43. Factors Influencing Complete Remission (CR) Rate in Patients ≥ 60 Years with Acute Myeloid Leukemia (AML): Report From the German AML Intergroup Study
44. Centrosome clustering and chromosomal (in)stability: A matter of life and death
45. Novel constitutional t(2;12)(q21;q22) in a patient with t(9;22)-negative chronic myelocytic leukemia
46. Centrosome aberrations in hematological malignancies
47. Checking out the Centrosome.
48. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase.
49. Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,
50. Deregulated EVI1 Expression Leads to Genomic Instability and G1 Cell Cycle Arrest
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.